The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Increasing Pressure for Increased Pharmacovgilance Capabilities

Posted by Jim Davis on Feb 17, 2017 11:00:00 AM

A few weeks ago, I published a post in this blog, Drug Safety Progressives - The Rise of the Pharmacovigilante. I was blown away by the positive response and resulting discussions. I even received a few requests for the t-shirt shown in the picture, but I’m sorry to say that our business model is based on software-as-a-service, not retail. But I digress… back to the Pharmacovigilantes…

Read More

Topics: Pharmacovigilance, Pharmacovigilantes, Pharmacovigiance 2.0

Using FAERS Data and Clinical Evidence to Compare HER2+ Antagonists

Posted by Andrea Demakas on Feb 9, 2017 7:30:00 AM

Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.

Read More

Topics: FAERS, Clinical Trials, Clinical Evidence, Breast Cancer

Drug Safety Progressives – The Rise of the Pharmacovigilante

Posted by Jim Davis on Feb 2, 2017 11:00:00 AM

The United States is a polarized place right now. Democrats vs. Republicans. Liberals vs. Conservatives. President Trump vs. the world. The divide runs deep and battle lines have been drawn. And while there is no escaping this highly publicized political chasm, there is another fight being played out in the shadows… The Drug Safety Progressives vs. the Drug Safety Conservatives.

I was at the DIA Pharmacovigilance and Risk Management conference last week, fittingly taking place in Washington D.C right after the inauguration and the women’s march.  The division was obvious.

Read More

Topics: Drug Safety, DIA

Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes

Posted by Brian Overstreet on Jan 26, 2017 10:30:00 AM

We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry.  Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally. 

Read More

Topics: Drug Safety, Health Outcomes

Real-Time Drug Safety Analysis with Evidex Alerts

Posted by Bob Kyle on Jan 20, 2017 10:30:00 AM

This week we launched Evidex Alerts, a new feature that provides our clients with real-time updates on the latest impactful drug safety news. This is a project that our development and analyst teams have worked on diligently for the last three months, and I am excited to announce that it became a reality this week. 

Read More

Topics: Drug Safety, Clinical Trials, Evidex

Will 2017 Be The Year of Drug Safety?

Posted by Brian Overstreet on Jan 12, 2017 1:53:43 PM

On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system.  Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist.  And I’m willing to say it.”  Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all.  Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me.  If you haven’t watched the report, I’d urge you to do so (link is here).

Read More

Topics: Drug Safety

Working Toward a Cure: The Foundation for Sarcoidosis Research

Posted by Jim Davis on Jan 5, 2017 11:00:00 AM

In November 2016, I was honored to be asked to join the Board of Directors of the Foundation for Sarcoidosis Research (FSR). The foundation began in 1999 as a grassroots organization, and now has expanded their efforts and impact to become the leader in supporting sarcoidosis research. I'm looking forward to using my experiences both as a sarcoidosis patient and in drug safety to contribute to the mission. Please visit www.stopsarcoidosis.org for more information. 

I originally wrote the post below for the FSR blog. The original can be seen here

Read More

Topics: Drug Safety, sarcoidoisis

Top 10 Free Report Downloads of 2016

Posted by Jim Davis on Dec 29, 2016 11:00:00 AM

Thanks to all of our readers for a great 2016. Below is a top 10 countdown of Advera Health's most downloaded reports of the year with links to access the free downloads.

Read More

Top 10 Advera Health Blog Posts of 2016

Posted by Jim Davis on Dec 22, 2016 11:00:00 AM

Happy Holidays! Thanks to all of our readers for a great 2016. Below is a top 10 countdown of Advera Health's most read blog posts of the year with links to the full post. Enjoy.

Read More

Looking Ahead - Drug Safety in 2017

Posted by Brian Overstreet on Dec 16, 2016 11:00:00 AM

As 2016 winds down, am I the only one who feels exhausted? 

Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.

Read More

Topics: Drug Safety, Clinical Evidence, Evidex

Subscribe to Email Updates